$INM
InMed Pharmaceuticals Inc. Stock $inm

$inm Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000121390023012859 Filed on February 17, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2021 Q4
Revenue	$1.034M	$469.8K	$265.1K
YoY Change	233.97%	77.22%
Cost Of Revenue	$841.4K	$338.6K	$153.5K
YoY Change	560.92%	120.54%
Gross Profit	$192.5K	$131.2K	$111.6K
YoY Change	5.61%	17.58%
Gross Profit Margin	18.62%	27.92%	42.08%
Selling, General & Admin	$1.413M	$1.465M	$1.637M
YoY Change	-26.23%	-10.5%	74.13%
% of Gross Profit	733.84%	1116.84%	1467.32%
Research & Development	$878.3K	$851.4K	$2.537M
YoY Change	-49.91%	-66.44%	169.9%
% of Gross Profit	456.24%	649.08%	2274.38%
Depreciation & Amortization	$50.69K	$49.05K	$49.80K
YoY Change	-4.97%	-1.51%	149.0%
% of Gross Profit	26.33%	37.4%	44.64%
Operating Expenses	$2.342M	$2.365M	$4.224M
YoY Change	-37.08%	-44.0%	118.84%
Operating Profit	-$1.998M	-$2.101M	-$4.112M
YoY Change	-43.55%	-48.9%	113.06%
Interest Expense	$152.8K	$136.0K	$7.230K
YoY Change	138.84%	1781.47%	-85.54%
% of Operating Profit
Other Income/Expense, Net			$22.06K
YoY Change			-106.13%
Pretax Income	-$1.996M	-$2.098M	-$4.283M
YoY Change	-42.56%	-51.01%	91.2%
Income Tax	$1.500K	$3.000K
% Of Pretax Income
Net Earnings	-$1.998M	-$2.101M	-$4.283M
YoY Change	-42.52%	-50.94%	91.2%
Net Earnings / Revenue	-193.24%	-447.25%	-1615.61%
Basic Earnings Per Share	-$0.60	-$0.91	-$7.73
Diluted Earnings Per Share	-$0.60	-$0.91	-$309.3K
COMMON SHARES
Basic Shares Outstanding	3.328M shares	936.8K shares	553.9K shares
Diluted Shares Outstanding	3.328M shares	2.301M shares	553.9K shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.647M	$11.50M	$11.33M
YoY Change	62.29%	1.5%	12.47%
Cash & Equivalents	$9.604M	$11.45M	$11.28M
Short-Term Investments	$43.06K	$43.05K	$45.42K
Other Short-Term Assets	$695.2K	$826.9K	$140.5K
YoY Change	-46.99%	488.52%	368.37%
Inventory	$1.330M	$1.614M	$988.8K
Prepaid Expenses
Receivables	$170.3K	$81.65K	$50.30K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.84M	$14.02M	$12.51M
YoY Change	35.39%	12.1%	22.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$753.2K	$703.9K	$1.097M
YoY Change	-24.89%	-35.81%	196.39%
Goodwill
YoY Change
Intangibles	$1.987M	$2.027M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$147.5K	$171.1K	$109.2K
YoY Change	35.77%	56.74%	991.8%
Total Long-Term Assets	$2.888M	$2.902M	$6.879M
YoY Change	-57.15%	-57.81%	358.58%
TOTAL ASSETS
Total Short-Term Assets	$11.84M	$14.02M	$12.51M
Total Long-Term Assets	$2.888M	$2.902M	$6.879M
Total Assets	$14.73M	$16.92M	$19.38M
YoY Change	-4.88%	-12.71%	64.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$737.5K	$770.8K	$1.707M
YoY Change	-56.0%	-54.84%	-17.95%
Accrued Expenses	$1.516M	$1.614M	$2.044M
YoY Change	-4.69%	-21.03%	2454.51%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$58.62K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.270M	$2.401M	$4.618M
YoY Change	-44.72%	-48.01%	114.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$72.79K	$183.9K	$598.6K
YoY Change	-85.25%	-69.28%	-65.99%
Total Long-Term Liabilities	$72.79K	$183.9K	$598.6K
YoY Change	-85.25%	-69.28%	-70.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.270M	$2.401M	$4.618M
Total Long-Term Liabilities	$72.79K	$183.9K	$598.6K
Total Liabilities	$2.342M	$2.585M	$5.216M
YoY Change	-49.07%	-50.45%	25.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$101.1M	-$99.06M
YoY Change
Common Stock	$77.62M	$74.86M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.39M	$14.34M	$14.17M
YoY Change
Total Liabilities & Shareholders Equity	$14.73M	$16.92M	$19.38M
YoY Change	-4.88%	-12.71%	64.97%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2021 Q4
OPERATING ACTIVITIES
Net Income	-$1.998M	-$2.101M	-$4.283M
YoY Change	-42.52%	-50.94%	91.2%
Depreciation, Depletion And Amortization	$50.69K	$49.05K	$49.80K
YoY Change	-4.97%	-1.51%	149.0%
Cash From Operating Activities	-$1.657M	-$2.713M	-$3.534M
YoY Change	-69.03%	-23.22%	95.24%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$35.56K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$128.2K	-$500.0K	$341.6K
YoY Change		-246.38%
Cash From Investing Activities	-$128.2K	-$500.0K	$306.0K
YoY Change	3511.27%	-263.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-63.70K	5.315M	-836.2K
YoY Change	117.33%	-735.68%	-112.0%
NET CHANGE
Cash From Operating Activities	-1.657M	-2.713M	-3.534M
Cash From Investing Activities	-128.2K	-500.0K	306.0K
Cash From Financing Activities	-63.70K	5.315M	-836.2K
Net Change In Cash	-1.849M	2.102M	-4.064M
YoY Change	-65.65%	-151.73%	-178.76%
FREE CASH FLOW
Cash From Operating Activities	-$1.657M	-$2.713M	-$3.534M
Capital Expenditures	$0.00	$0.00	-$35.56K
Free Cash Flow	-$1.657M	-$2.713M	-$3.498M
YoY Change	-69.01%	-22.44%	93.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39685
	dei	Entity Registrant Name EntityRegistrantName	INMED PHARMACEUTICALS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1428279
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Suite 310 - 815 W. Hastings Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Vancouver
	dei	Entity Address City Or Town EntityAddressCityOrTown	B.C
	dei	Entity Address Country EntityAddressCountry	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V6C 1B4
	dei	City Area Code CityAreaCode	(604)
	dei	Local Phone Number LocalPhoneNumber	669-7207
	dei	Security12b Title Security12bTitle	Common Shares, no par value
	dei	Trading Symbol TradingSymbol	INM
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	43053	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3328196	shares
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	44804	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11452578	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6176866	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	81647	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	88027	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1613506	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2490854	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	826931	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	797225	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	14017715	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	9597776	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	703922	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	904252	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2026929	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2108915	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	171130	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	176637	usd
CY2022Q4	us-gaap	Assets Assets	16919696	usd
CY2022Q2	us-gaap	Assets Assets	12787580	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1970265	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2415265	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	414307	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	404276	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16171	usd
CY2022Q2	inm	Acquisition Consideration Payable AcquisitionConsiderationPayable	500000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2400743	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3319541	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	183902	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	389498	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2584645	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3709039	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1589992	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1589992	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	650667	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	650667	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	74862424	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	70718461	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	38407932	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31684098	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99063874	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93452587	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14335051	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9078541	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16919696	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12787580	usd
CY2022Q4	us-gaap	Revenues Revenues	469783	usd
	us-gaap	Revenues Revenues	790571	usd
CY2021Q4	us-gaap	Revenues Revenues	265092	usd
	us-gaap	Revenues Revenues	265092	usd
CY2022Q4	us-gaap	Cost Of Revenue CostOfRevenue	338620	usd
CY2021Q4	us-gaap	Cost Of Revenue CostOfRevenue	153537	usd
	us-gaap	Cost Of Revenue CostOfRevenue	573654	usd
	us-gaap	Cost Of Revenue CostOfRevenue	153537	usd
	inm	Inventory Writedownin Dollars Per Share InventoryWritedowninDollarsPerShare	576772	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	131163	usd
CY2021Q4	us-gaap	Gross Profit GrossProfit	111555	usd
	us-gaap	Gross Profit GrossProfit	-359855	usd
	us-gaap	Gross Profit GrossProfit	111555	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	851356	usd
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2537070	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2230009	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4028322	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1464879	usd
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1836786	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3025356	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3209653	usd
CY2022Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	49049	usd
CY2021Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	49797	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	98097	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	78329	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	2365284	usd
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	4423653	usd
	us-gaap	Operating Expenses OperatingExpenses	5353462	usd
	us-gaap	Operating Expenses OperatingExpenses	7316304	usd
CY2022Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	115797	usd
CY2021Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	26277	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	188384	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	31425	usd
CY2022Q4	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	20237	usd
CY2021Q4	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	3007	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-76554	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-81105	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2098087	usd
CY2021Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4282814	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5601487	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7254429	usd
CY2022Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-9800	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2101087	usd
CY2021Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4282814	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5611287	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7254429	usd
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.73
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	516933	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.03
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2300526	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	553894	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1583073	shares
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-5507	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-6030	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	18705	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2285	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-508871	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	296437	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7376567	usd
CY2021Q3	inm	Stock Issued During Period Value Issued For Private Placement StockIssuedDuringPeriodValueIssuedForPrivatePlacement	11999686	usd
CY2021Q3	inm	Share Issuance Costs ShareIssuanceCosts	-2034167	usd
CY2021Q3	inm	Agents Warrants AgentsWarrants	739920	usd
CY2021Q3	inm	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	139	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2971615	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	111142	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	15221672	usd
CY2021Q4	inm	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	176	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3013500	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-4282814	usd
CY2021Q4	us-gaap	Share Based Compensation ShareBasedCompensation	214779	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	14167313	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9078541	usd
CY2022Q3	inm	Stock Issued During Period Value Issued For Private Placement StockIssuedDuringPeriodValueIssuedForPrivatePlacement	5999946	usd
CY2022Q3	inm	Share Issuance Costs ShareIssuanceCosts	-1129343	usd
CY2022Q3	inm	Agents Investment Options AgentsInvestmentOptions	451897	usd
CY2022Q3	inm	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	419	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3510200	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	116680	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	11007940	usd
CY2022Q4	inm	Stock Issued During Period Value Issued For Private Placement StockIssuedDuringPeriodValueIssuedForPrivatePlacement	5999844	usd
CY2022Q4	inm	Share Issuance Costs ShareIssuanceCosts	-881923	usd
CY2022Q4	inm	Agents Investment Options AgentsInvestmentOptions	239586	usd
CY2022Q4	inm	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	53	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2101087	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	70638	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14335051	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5611287	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7254429	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	98097	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	78329	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	187318	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	325921	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	197767	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	126080	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-11355	usd
	inm	Interest Incomeaccrued Received On Shortterm Investments InterestIncomeaccruedReceivedOnShorttermInvestments	-418	usd
	inm	Unrealized Gain On Foreign Exchange UnrealizedGainOnForeignExchange	-2167	usd
	inm	Unrealized Gain On Foreign Exchange UnrealizedGainOnForeignExchange	-1038	usd
	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
	inm	Bad Debts BadDebts	25085	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-300576	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	501700	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	29706	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	16171	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3248	usd
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	209112	usd
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	125123	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4968639	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6187725	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-847374	usd
	inm	Cash Acquired From Acquisition Of Bay Medica CashAcquiredFromAcquisitionOfBayMedica	91566	usd
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35555	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-500000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	56011	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12000262	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12000001	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1255911	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1294247	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	232202	usd
	inm	Settlement Of Debt Upon Acquisition Of Subsidiary SettlementOfDebtUponAcquisitionOfSubsidiary	425000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10744351	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10048552	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5275712	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3916838	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6176866	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7363126	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11452578	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11279964	usd
	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><b>1.</b></td><td style="text-align: justify"><b>CORPORATE INFORMATION AND CONTINUING OPERATIONS</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Business</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the <i>Business Corporations Act</i> of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s office and principal place of business is located at #310 – 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Liquidity</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Through December 31, 2022, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of approximately $5.6 million and $7.3 million for the six months ended December 31, 2022 and 2021, respectively. In addition, the Company had an accumulated deficit of approximately $99.1 million at December 31, 2022. The Company expects to continue to generate operating losses for the foreseeable future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of the issuance date of these condensed consolidated interim financial statements, the Company expects its cash and cash equivalents of $11.5 million as of December 31, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into the last quarter of calendar 2023, depending on the level and timing of realizing revenues from the sale of BayMedica inventory as well as the level and timing of the Company operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. As a result of the recurring losses and requirement for cash in the last quarter of calendar 2023 or the first quarter of calendar 2024, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its commitments, realize its assets and discharge its liabilities in the normal course. These condensed consolidated interim financial statements do not reflect adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going concern and such adjustments could be material.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>COVID-19 Impacts</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The full extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to the Company’s condensed consolidated interim financial statements as of and for the three and six months ended December 31, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to the Company’s consolidated financial statements in future reporting periods.</p>
	us-gaap	Profit Loss ProfitLoss	5600000	usd
	us-gaap	Profit Loss ProfitLoss	7300000	usd
CY2022Q4	inm	Accumulated Deficit AccumulatedDeficit	99100000	usd
CY2022Q4	inm	Cash And Cash Equivalent CashAndCashEquivalent	11500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these consolidated financial statements are the estimate of useful life of intangible assets, the application of the going concern assumption, and determining the fair value of share-based payments and warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><b><i> </i></b></p>
CY2022Q4	inm	Concentration Risk Percentage ConcentrationRiskPercentage	0.67	pure
	inm	Concentration Risk Percentage ConcentrationRiskPercentage	0.49	pure
	inm	Gross Outstanding Percentage GrossOutstandingPercentage	0.55	pure
CY2021Q4	inm	Concentration Risk Percentage ConcentrationRiskPercentage	0.76	pure
	inm	Concentration Risk Percentage ConcentrationRiskPercentage	0.76	pure
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	208737	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	292577	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	798813	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1724851	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	605956	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	473426	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1613506	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2490854	usd
	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	67866	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1420722	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1420722	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	716800	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	516470	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net Excluding Capital Leased Assets PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets	703922	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net Excluding Capital Leased Assets PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets	904252	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	8056	usd
	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	16111	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	6246	usd
	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	10463	usd
CY2022Q4	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	90389	usd
	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	180633	usd
CY2021Q4	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	88265	usd
	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	109608	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1736420	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1736420	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2022Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Asset Acquired In Place Leases FiniteLivedIntangibleAssetAcquiredInPlaceLeases	2927420	usd
CY2022Q2	us-gaap	Finite Lived Intangible Asset Acquired In Place Leases FiniteLivedIntangibleAssetAcquiredInPlaceLeases	2927420	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	900491	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	818505	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2026929	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2108915	usd
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P12Y
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P5Y
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	40993	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	81986	usd
CY2021Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43551	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	78424	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	156847	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	156847	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	156847	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	156847	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1321117	usd
CY2022Q4	inm	Finite Lived Intangible Asset Net FiniteLivedIntangibleAssetNet	2026929	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	770807	usd
CY2022Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1166068	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	742515	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	839638	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	387552	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	139120	usd
	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	69391	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	270439	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	1970265	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	2415265	usd
CY2022Q4	inm	Total Common Share Value TotalCommonShareValue	410376	usd
	inm	Total Common Share Value TotalCommonShareValue	263372	usd
	inm	Share Of Number Of Cancelled ShareOfNumberOfCancelled	-179231	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	18.5
CY2017Q1	inm	Issued And Outstanding Percentage IssuedAndOutstandingPercentage	0.20	pure
CY2022Q4	inm	Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross	40288	shares
CY2022Q2	inm	Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross	18163	shares
	inm	Issued And Outstanding Percentage IssuedAndOutstandingPercentage	0.20	pure
CY2022Q2	inm	Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbers SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers	55603	shares
	inm	Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	128.59
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	61720	shares
	inm	Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding Weighted Average Exercise Price Granted ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted	1.85
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	3845	shares
	inm	Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding Weighted Average Exercise Price Expired Forfeited ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited	42.84
CY2022Q4	inm	Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbers SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers	113478	shares
	inm	Share Based Compensation Arrangement By Shares Based Payments Awards Option Outstandings Weighted Average Exercise Price ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice	58.22	shares
	inm	Number Of Vested And Exercisable NumberOfVestedAndExercisable	26813	shares
	inm	Weighted Average Exercise Price Vested And Exercisable WeightedAverageExercisePriceVestedAndExercisable	203.76
	inm	Number Of Unvested NumberOfUnvested	86665	shares
	inm	Weighted Average Exercise Price Unvested WeightedAverageExercisePriceUnvested	13.2
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	21.04
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0374	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0117	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y3M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.2298	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.9715	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	inm	Weighted Average Forfeiture Rate WeightedAverageForfeitureRate	0.05	pure
CY2022	inm	Weighted Average Forfeiture Rate WeightedAverageForfeitureRate	0.05	pure
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	70638	usd
CY2021Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	214779	usd
	inm	Allocated Share Based Compensation Expenses AllocatedShareBasedCompensationExpenses	109113	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	78205	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	160554	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y7M6D
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	433190	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	176360	usd
CY2022Q4	us-gaap	Receivable With Imputed Interest Net Amount ReceivableWithImputedInterestNetAmount	11341	usd
CY2022Q4	us-gaap	Present Value Of Future Minimum Lease Payments Sale Leaseback Transactions PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions	598209	usd
	inm	Current Portion Of Lease Liabilities CurrentPortionOfLeaseLiabilities	414307	usd
CY2022Q4	inm	Operating Lease Liabilities Noncurrent OperatingLeaseLiabilitiesNoncurrent	183902	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	113478	shares
CY2022Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2101087	usd
CY2021Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4282814	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5611287	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7254429	usd
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.03
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2300526	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	553894	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1583073	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	516933	shares
CY2022Q4	us-gaap	Revenues Revenues	469783	usd
CY2021Q4	us-gaap	Revenues Revenues	265092	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	338620	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	153537	usd
CY2022Q4	us-gaap	Costs And Expenses CostsAndExpenses	-2365284	usd
CY2021Q4	us-gaap	Costs And Expenses CostsAndExpenses	-4423653	usd
CY2022Q4	us-gaap	Other Income OtherIncome	133034	usd
CY2021Q4	us-gaap	Other Income OtherIncome	29284	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2101087	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4282814	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11452578	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11279964	usd
	us-gaap	Revenues Revenues	790571	usd
	us-gaap	Revenues Revenues	265092	usd
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	573654	usd
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	153537	usd
CY2022Q4	us-gaap	Inventory Adjustments InventoryAdjustments	-576772	usd
	us-gaap	Costs And Expenses CostsAndExpenses	-5353462	usd
	us-gaap	Costs And Expenses CostsAndExpenses	-7316304	usd
	us-gaap	Other Income OtherIncome	102030	usd
	us-gaap	Other Income OtherIncome	-49680	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5611287	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7254429	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11452578	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11279964	usd
CY2022Q3	us-gaap	Common Unit Issued CommonUnitIssued	44931	shares
CY2022Q3	inm	Estimated Fair Value Common Shares EstimatedFairValueCommonShares	451897	usd
CY2022Q4	us-gaap	Common Unit Issued CommonUnitIssued	118182	shares
CY2022Q4	inm	Estimated Fair Value Common Shares EstimatedFairValueCommonShares	239587	usd
CY2022Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	63871	usd
CY2021Q3	inm	Estimated Fair Value Common Shares EstimatedFairValueCommonShares	739920	usd
CY2021Q4	us-gaap	Common Unit Issued CommonUnitIssued	2050000	shares
CY2021Q4	inm	Estimated Fair Value Common Shares EstimatedFairValueCommonShares	3013500	usd
CY2022Q4	inm	Cost Of Services Directs Materials CostOfServicesDirectsMaterials	2353861	usd
CY2022	us-gaap	Capital Expenditure Discontinued Operations CapitalExpenditureDiscontinuedOperations	1592951	usd
CY2022	inm	Expenditure Balance ExpenditureBalance	760910	usd
	us-gaap	Production Costs ProductionCosts	526704	usd
CY2022Q4	inm	Guaranteed Investment GuaranteedInvestment	43053	usd
CY2022Q2	inm	Guaranteed Investment GuaranteedInvestment	44676	usd
	inm	Warrants To Purchase WarrantsToPurchase	700	shares
CY2022Q4	us-gaap	Shares Issued SharesIssued	700	shares
CY2022Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	300000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	1551470	cad
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	1145450	usd
CY2022Q4	us-gaap	Cash Cash	11023864	usd
CY2022Q2	us-gaap	Cash Cash	5087615	usd
CY2022Q4	us-gaap	Other Minority Interests OtherMinorityInterests	428714	usd
CY2022Q2	us-gaap	Other Minority Interests OtherMinorityInterests	1089251	usd
CY2022Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	43053	usd
CY2022Q2	us-gaap	Other Short Term Investments OtherShortTermInvestments	44676	usd
CY2022Q4	inm	Short Term Investment ShortTermInvestment	11495631	usd
CY2022Q2	inm	Short Term Investment ShortTermInvestment	6221670	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2400743	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3181316	usd
CY2022Q4	inm	Working Capital Surplus workingCapitalSurplus	11616972	usd
CY2022Q2	inm	Working Capital Surplus workingCapitalSurplus	6416460	usd
	us-gaap	Legal Fees LegalFees	491749	usd
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	inm	Interest Incomeaccrued Received On Shortterm Investments InterestIncomeaccruedReceivedOnShorttermInvestments		usd
	inm	Bad Debts BadDebts		usd
	inm	Cash Acquired From Acquisition Of Bay Medica CashAcquiredFromAcquisitionOfBayMedica		usd
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
	inm	Settlement Of Debt Upon Acquisition Of Subsidiary SettlementOfDebtUponAcquisitionOfSubsidiary		usd
	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2022Q4	inm	Aggregate Intrinsic Value Cancelled AggregateIntrinsicValueCancelled		usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive		usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.03
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.54
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.73
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1583073	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2300526	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	516933	shares
	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	553894	shares
CY2021Q4	us-gaap	Inventory Adjustments InventoryAdjustments		usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001728328

Files In Submission

Name	View Source	Status
0001213900-23-012859-index-headers.html	Edgar Link	pending
0001213900-23-012859-index.html	Edgar Link	pending
0001213900-23-012859.txt	Edgar Link	pending
0001213900-23-012859-xbrl.zip	Edgar Link	pending
f10q1222ex31-1_inmed.htm	Edgar Link	pending
f10q1222ex31-2_inmed.htm	Edgar Link	pending
f10q1222ex32-1_inmed.htm	Edgar Link	pending
f10q1222ex32-2_inmed.htm	Edgar Link	pending
f10q1222_inmedpharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
inm-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
inm-20221231_cal.xml	Edgar Link	unprocessable
inm-20221231_def.xml	Edgar Link	unprocessable
inm-20221231_lab.xml	Edgar Link	unprocessable
inm-20221231_pre.xml	Edgar Link	unprocessable
f10q1222_inmedpharma_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INM
InMed Pharmaceuticals Inc. Stock $inm

2023 Q1 Form 10-Q Financial Statement

#000121390023012859 Filed on February 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM InMed Pharmaceuticals Inc. Stock $inm

2023 Q1 Form 10-Q Financial Statement

#000121390023012859 Filed on February 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM
InMed Pharmaceuticals Inc. Stock $inm